Expanding Access to Advanced Prostate Cancer Screening in Emerging Markets
The Challenge:
The Silent Burden of Prostate Cancer Globally
Prostate cancer is a significant health concern worldwide, with disproportionately high mortality rates in emerging markets due to late diagnosis and limited access to advanced screening technologies.
Our Solution: Affordable, Automated Early Detection
GHMIGROUP facilitates access to IsoPSA™ diagnostics from Cleveland Diagnostics through an exclusive sub-licensing model. IsoPSA™ represents a breakthrough in prostate cancer screening, offering:
Enhanced Accuracy:More precise than traditional PSA tests, reducing unnecessary biopsies.
Automation Potential:Suitable for deployment in diverse healthcare settings.
Affordability:Designed to be accessible in resource-constrained environments.
Benefits & Impact
Drives earlier detection of prostate cancer, improving treatment outcomes and saving lives.
Reduces the burden on healthcare systems by minimizing unnecessary procedures.
Empowers local healthcare providers with advanced diagnostic capabilities.
Contributes to health equity by making cutting-edge technology available where it’s needed most.
Partnering for Deployment
We work with healthcare ministries, hospitals, clinics, and NGOs in Sub-Saharan Africa, the Caribbean, and other emerging markets to integrate IsoPSA™ into local health systems.
